Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women
Information source: Wyeth
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Postmenopause
Intervention: Conjugated Estrogen Cream (Premarin®) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth
Summary
This post-marketing study will provide local safety and tolerance data on the use of
Premarin® vaginal cream.
Clinical Details
Official title: A Postmarketing Surveillance Study Evaluating the Tolerability and Safety of PREMARIN VAGINAL CREAM in Indian Postmenopausal Women
Study design: Other
Eligibility
Minimum age: 40 Years.
Maximum age: 65 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Patients in whom Premarin vaginal cream is indicated.
- In the opinion of the investigator, sufficient intelligence and motivation for the
patient to continue throughout the study.
- Provide signed informed consent.
Exclusion Criteria:
- Patients not willing to give informed consent.
Locations and Contacts
Additional Information
Starting date: September 2005
Ending date: October 2006
Last updated: December 20, 2007
|
